Community-Acquired MRSA Treatment Approach

Infection Site-Specific Treatment

The Infectious Diseases Society of America recommends empirical antibiotic therapy for suspected community-acquired MRSA infections, with vancomycin or linezolid for severe infections requiring hospitalization, and trimethoprim-sulfamethoxazole, doxycycline, or clindamycin for outpatient skin and soft tissue infections 1, 2
For purulent cellulitis or abscesses, incision and drainage is the primary intervention, followed by empirical oral antibiotics for 5-10 days 2
Trimethoprim-sulfamethoxazole is the first-line choice for empirical oral antibiotics, with 98% susceptibility in most communities 2
Clindamycin 600 mg PO three times daily is an alternative option, but only if local resistance rates are <10% 3, 2
Linezolid 600 mg PO twice daily is an alternative for resistant cases 2

Severe community-acquired pneumonia has critical recognition features, including influenza-like prodrome with fever >39°C, tachycardia >140 bpm, hemoptysis, hypotension, multilobar infiltrates, marked leukopenia, and very high C-reactive protein 4, 5
Empirical treatment for severe CAP with MRSA suspicion includes vancomycin IV or linezolid 600 mg IV/PO twice daily for 7-21 days 1
Combination therapy is essential for PVL-positive CA-MRSA pneumonia, with recommended combinations including vancomycin + rifampin, or clindamycin + linezolid 4, 5

CA-MRSA is genetically distinct from hospital-acquired strains, typically more susceptible to non-β-lactam antibiotics, and frequently carries the Panton-Valentine Leukocidin (PVL) toxin gene 4, 3, 1

Dosing adjustments for children include vancomycin IV with standard dosing, clindamycin 10-13 mg/kg/dose IV every 6-8 hours, and linezolid 600 mg twice daily for >12 years or 10 mg/kg every 8 hours for <12 years 1, 2

Common errors in CA-MRSA management include using β-lactams alone, avoiding vancomycin monotherapy for severe PVL-positive pneumonia, and not assuming clindamycin susceptibility 3, 4, 5

Indications for hospitalization and IV antibiotics include severe or extensive disease, rapid progression, signs of systemic illness, failed outpatient management, immunosuppression, and difficult-to-drain locations 2
A step-down strategy involves transitioning to oral TMP-SMX or tetracycline after initial clinical response and documented susceptibility, and continuing total antibiotic course of 7-21 days depending on infection severity and site 3, 1